JP2017514800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514800A5 JP2017514800A5 JP2016560809A JP2016560809A JP2017514800A5 JP 2017514800 A5 JP2017514800 A5 JP 2017514800A5 JP 2016560809 A JP2016560809 A JP 2016560809A JP 2016560809 A JP2016560809 A JP 2016560809A JP 2017514800 A5 JP2017514800 A5 JP 2017514800A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- composition
- polypeptide
- nucleic acid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975687P | 2014-04-04 | 2014-04-04 | |
| US61/975,687 | 2014-04-04 | ||
| PCT/US2015/024400 WO2015154059A2 (en) | 2014-04-04 | 2015-04-04 | Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114165A Division JP2020176123A (ja) | 2014-04-04 | 2020-07-01 | Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514800A JP2017514800A (ja) | 2017-06-08 |
| JP2017514800A5 true JP2017514800A5 (https=) | 2018-05-17 |
| JP6728056B2 JP6728056B2 (ja) | 2020-07-22 |
Family
ID=54241451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560809A Expired - Fee Related JP6728056B2 (ja) | 2014-04-04 | 2015-04-04 | Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること |
| JP2020114165A Pending JP2020176123A (ja) | 2014-04-04 | 2020-07-01 | Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114165A Pending JP2020176123A (ja) | 2014-04-04 | 2020-07-01 | Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9850293B2 (https=) |
| EP (1) | EP3129066B1 (https=) |
| JP (2) | JP6728056B2 (https=) |
| KR (1) | KR20160141751A (https=) |
| CN (1) | CN106170305A (https=) |
| AU (1) | AU2015240460A1 (https=) |
| BR (1) | BR112016023025A2 (https=) |
| CA (1) | CA2943297A1 (https=) |
| IL (1) | IL248046B (https=) |
| MX (1) | MX2016013025A (https=) |
| RU (1) | RU2692104C2 (https=) |
| WO (1) | WO2015154059A2 (https=) |
| ZA (1) | ZA201607375B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CA2881582A1 (en) | 2012-08-03 | 2014-02-06 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| DK2993983T3 (da) | 2013-05-08 | 2020-05-18 | Cedars Sinai Medical Center | Målretningskorroler til tumortoksicitet og mri |
| EP3096773B1 (en) | 2014-01-17 | 2020-07-01 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
| EA201892797A1 (ru) * | 2016-05-27 | 2019-06-28 | Седарс-Синаи Медикал Сентер | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака |
| CN106474472B (zh) * | 2016-10-11 | 2021-06-08 | 连云港市第一人民医院 | 肿瘤曲妥珠单抗靶向anti-miR-21纳米粒子及其制备方法 |
| EP3735245A4 (en) * | 2018-01-02 | 2021-10-27 | Cedars-Sinai Medical Center | NANOPARTICLES ALLOWING TARGETED ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| KR102182985B1 (ko) * | 2019-01-03 | 2020-11-26 | 주식회사 바이오이즈 | pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체 |
| US20220088213A1 (en) * | 2019-01-03 | 2022-03-24 | Sung Chun Kim | Drug delivery system using ph-dependent cell-penetrating peptides, and composite thereof with drug |
| US20230174636A1 (en) * | 2020-05-12 | 2023-06-08 | Rush University Medical Center | Compositions and methods for treating cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| US6855135B2 (en) | 2000-11-29 | 2005-02-15 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
| WO2002062823A2 (en) | 2001-02-02 | 2002-08-15 | Yale University | Peptides for facilitating composite receptor expression and translocation of macromolecules |
| WO2002094318A1 (en) | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| EP1374812A1 (en) | 2002-06-28 | 2004-01-02 | Biopol Co., Ltd. | Multilayered microporous foam dressing and method for manufacturing the same |
| US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
| US7205387B2 (en) | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
| TWI355894B (en) | 2003-12-19 | 2012-01-11 | Du Pont | Herbicidal pyrimidines |
| US20060014712A1 (en) | 2004-05-30 | 2006-01-19 | Cemines, Inc. | Controlled delivery of therapeutic compounds |
| US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
| US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| US20110052697A1 (en) | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
| WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2009151539A1 (en) | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
| WO2010078517A2 (en) | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CA2772660A1 (en) | 2009-09-01 | 2011-03-10 | Northwestern University | Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers |
| US20130065778A1 (en) * | 2010-01-26 | 2013-03-14 | Yale University | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy |
| JP6382185B2 (ja) | 2012-05-22 | 2018-08-29 | スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ | 創傷治療のための装置および方法 |
| CA2881582A1 (en) | 2012-08-03 | 2014-02-06 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| DK2993983T3 (da) | 2013-05-08 | 2020-05-18 | Cedars Sinai Medical Center | Målretningskorroler til tumortoksicitet og mri |
| EP3096773B1 (en) | 2014-01-17 | 2020-07-01 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
| SG11201701402QA (en) | 2014-08-27 | 2017-03-30 | Peptimed Inc | Anti-tumor compositions and methods |
-
2015
- 2015-04-04 US US14/678,972 patent/US9850293B2/en not_active Expired - Fee Related
- 2015-04-04 MX MX2016013025A patent/MX2016013025A/es unknown
- 2015-04-04 CA CA2943297A patent/CA2943297A1/en not_active Abandoned
- 2015-04-04 RU RU2016140214A patent/RU2692104C2/ru active
- 2015-04-04 CN CN201580018801.3A patent/CN106170305A/zh active Pending
- 2015-04-04 WO PCT/US2015/024400 patent/WO2015154059A2/en not_active Ceased
- 2015-04-04 EP EP15773654.7A patent/EP3129066B1/en not_active Not-in-force
- 2015-04-04 JP JP2016560809A patent/JP6728056B2/ja not_active Expired - Fee Related
- 2015-04-04 AU AU2015240460A patent/AU2015240460A1/en not_active Abandoned
- 2015-04-04 BR BR112016023025-6A patent/BR112016023025A2/pt not_active Application Discontinuation
- 2015-04-04 KR KR1020167028017A patent/KR20160141751A/ko not_active Ceased
-
2016
- 2016-09-26 IL IL248046A patent/IL248046B/en active IP Right Grant
- 2016-10-26 ZA ZA2016/07375A patent/ZA201607375B/en unknown
-
2017
- 2017-11-17 US US15/816,881 patent/US20180066033A1/en not_active Abandoned
-
2020
- 2020-07-01 JP JP2020114165A patent/JP2020176123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514800A5 (https=) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| JP2016535009A5 (https=) | ||
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| Izar et al. | Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer | |
| JP2008502584A5 (https=) | ||
| JP2019526578A5 (https=) | ||
| WO2018115231A3 (en) | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer | |
| JP2010540453A5 (https=) | ||
| JP2019506862A5 (https=) | ||
| JP2021502980A5 (https=) | ||
| JP2017533920A5 (https=) | ||
| JP2010509331A5 (https=) | ||
| JP2015532292A5 (https=) | ||
| RU2016119999A (ru) | Способы лечения онкологических заболеваний | |
| JP2013166763A5 (https=) | ||
| JP6101827B2 (ja) | がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤 | |
| JP2015512398A5 (https=) | ||
| JP2016530233A5 (https=) | ||
| JP2017533223A5 (https=) | ||
| JP2016515628A5 (https=) | ||
| JP2015514756A5 (https=) | ||
| MX2017001012A (es) | Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo. | |
| JP2016526021A5 (https=) | ||
| JP2010523696A5 (https=) |